# An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

> **NCT05276830** · PHASE2 · TERMINATED · sponsor: **BioXcel Therapeutics Inc** · enrollment: 5 (actual)

## Conditions studied

- Agitation
- Dementia

## Interventions

- **DRUG:** BXCL501
- **DRUG:** BXCL501
- **DRUG:** Placebo film

## Key facts

- **NCT ID:** NCT05276830
- **Lead sponsor:** BioXcel Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-08
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-04-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study was terminated for business reasons; not due to safety or efficacy concerns
- **Last updated:** 2023-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05276830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05276830, "An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05276830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*